Antibody-mediated rejection-An ounce of prevention is worth a pound of cure

American Journal of Transplantation

Volumn 11, Issue 6, 2011, Pages 1131-1139

  Bradley, J A ^a   Baldwin, W M ^b   Bingaman, A ^c   Ellenrieder, C ^d   Gebel, H M ^e   Glotz, D ^f   Kirk, A D ^g  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Cleveland Diagnostics   (United States)

^c TEXAS TRANSPLANT INSTITUTE   (United States)

^d Roche Organ Transplantation Research Foundation (ROTRF)   (Switzerland)

^e EMORY UNIVERSITY HOSPITAL   (United States)

^f SAINT LOUIS HOSPITAL   (France)

^g EMORY UNIVERSITY   (United States)

Author keywords

Alloantibody; antibody mediated rejection; desensitization; immune monitoring; kidney paired donation

Indexed keywords

ALLOANTIBODY; BORTEZOMIB; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; RITUXIMAB;

ACUTE ANTIBODY MEDIATED REJECTION; ANTIBODY RESPONSE; CELLULAR IMMUNITY; CONFERENCE PAPER; DRUG MEGADOSE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MEDICAL RESEARCH; PLASMAPHERESIS; PRIORITY JOURNAL;

ANTIBODY FORMATION; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; ISOANTIBODIES; KIDNEY TRANSPLANTATION;

EID: 79958803569     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03581.x     Document Type: Conference Paper

References (46)

1. Kaneko Y, Nimmerjahn F, Ravetch JV,. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670-673. (Pubitemid 44201145)
2. Murata K, Fox-Talbot K, Qian Z, et al,. Synergistic deposition of C4d by complement and non-complement activating antibodies in cardiac transplants. Am J Transplant 2007; 7: 2605-2614. (Pubitemid 47561614)
3. Platt JL,. C4d and the fate of organ allografts. J Am Soc Nephrol 2002; 13: 2417-2419. (Pubitemid 34925253)
4. Haas M, Rahman MH, Racusen LC, et al,. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: Correlation with histologic findings. Am J Transplant 2006; 6: 1829-1840. (Pubitemid 44024954)
5. Racusen LC, Colvin RB, Solez K, et al,. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714. (Pubitemid 36745243)
6. Sis B, Jhangri GS, Bunnag S, et al,. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
7. Zhang X, Reed EF,. Effect of antibodies on endothelium. Am J Transplant 2009; 9: 2459-2465.
8. Minami K, Murata K, Lee C-Y, et al,. C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats. Am J Transplant 2006; 6: 923-932. (Pubitemid 44356642)
9. Colvin RB,. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046-1056. (Pubitemid 46536891)
10. Peng Q, Li K, Patel H, et al,. Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol 2006; 176: 3330-3341. (Pubitemid 43363979)
11. Zhou W, Patel H, Li K, et al,. Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. Blood 2006; 107: 2461-2469. (Pubitemid 43345568)
12. Heeger PS, Lalli PN, Lin F, et al,. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005; 201: 1523-1530. (Pubitemid 40720998)
13. Wang H, Jiang J, Liu W, et al,. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation 2005; 79: 1121-1127. (Pubitemid 40664008)
14. Locke JE, Magro CM, Singer AL, et al,. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235.
15. de Vries B, Kohl J, Leclercq WK, et al,. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 2003; 170: 3883-3889. (Pubitemid 36359260)
16. Gueler F, Rong S, Gwinner W, et al,. Complement 5a receptor inhibition improves renal allograft survival. J Am Soc Nephrol 2008; 19: 2302-2312.
17. Wagner E, Frank MM,. Therapeutic potential of complement modulation. Nat Rev Drug Discov 2010; 9: 43-56.
18. Navratil JS, Watkins SC, Wisnieski JJ, Ahearn JM,. The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol 2001; 166: 3231-3239. (Pubitemid 33117322)
19. Mitchell DA, Pickering MC, Warren J, et al,. C1q deficiency and autoimmunity: The effects of genetic background on disease expression. J Immunol 2002; 168: 2538-2543. (Pubitemid 34171862)
20. Csencsits K, Burrell BE, Lu G, et al,. The classical complement pathway in transplantation: Unanticipated protective effects of C1q and role in inductive antibody therapy. Am J Transplant 2008; 8: 1622-1630.
21. Pruitt SK, Baldwin WM, 3rd, Marsh HC, et al,. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation 1991; 52: 868-873.
22. Pruitt SK, Bollinger RR, Collins BH, et al,. Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts. Transplantation 1997; 63: 900-902. (Pubitemid 27150599)
23. Patel R, Terasaki PI,: Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
24. Oldfather JW, Anderson CB, Phelan DL, et al,. Prediction of crossmatch outcome in highly sensitized dialysis patients based on the identification of serum HLA antibodies. Transplantation 1986; 42: 267-270. (Pubitemid 16020749)
25. Bray RA, Nickerson PW, Kerman RH, Gebel HM,. Evolution of HLA antibody detection: Technology emulating biology. Immunol Res 2004; 29: 41-54.
26. Pei R, Wang G, Tarsitani C, et al,. Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum Immunol 1998; 59: 313-322. (Pubitemid 28225990)
27. Pei R, Lee JH, Shih NJ, et al,. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43-49. (Pubitemid 36139693)
28. Bray RA, Nolen JD, Larsen C, et al,. Transplanting the highly sensitized patient: The Emory algorithm. Am J Transplant 2006; 6: 2307-2315. (Pubitemid 44359415)
29. Cecka, JM,. Calculated PRA (CPRA): The new measure of sensitization from transplant candidates. Am. J Transplant 2010; 10: 26-29.
30. Gebel HM, Moussa O, Eckels DD, Bray RA,. Donor-reactive HLA antibodies in renal allograft recipients: Considerations, complications, and conundrums. Hum Immunol 2009; 70: 610-617.
31. Lefaucheur C, Loupy A, Hill GS, et al,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
32. Archdeacon P, et al,. Meeting Report: The FDA conference on Antibody mediated rejection. Am J Transplant 2011; 11: 896-906.
33. Jordan SC, Toyoda M, Vo AA,. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009; 88: 1-6.
34. Glotz D, Antoine C, Julia P, et al,. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758-760. (Pubitemid 36342618)
35. Jordan SC, Vo A, Bunnapradist S, et al,. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631-636. (Pubitemid 37071992)
36. Vo AA, Lukovsky M, Toyoda M, et al,. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251. (Pubitemid 352008439)
37. Montgomery RA, Zachary AA,. Transplanting patients with a positive donor-specific crossmatch: A single center's perspective. Pediatr Transplant 2004; 8: 535-542. (Pubitemid 40052349)
38. Gloor JM, DeGoey SR, Pineda AA, et al,. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3: 1017-1023. (Pubitemid 36917550)
39. Vieira CA, Agarwal A, Book BK, et al,. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542-548. (Pubitemid 38282809)
40. Wahrmann M, Haidinger M, Körmöczi GF, et al,. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89: 1385-1390.
41. Cecka JM,. Calculated PRA (CPRA): The new measure of sensitization for transplant candidates. Am J Transplant 2010; 10: 26-29.
42. Amico P, Hönger G, Mayr M, et al,. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681-1688.
43. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al,. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324-331.
44. Gentry SE, Montgomery RA, Segev DL,. Kidney paired donation: Fundamentals, limitations, and expansions. Am J Kidney Dis 2011; 57: 144-51.
45. Bingaman AW, Wright FH, Murphey CL,. Kidney paired donation in live-donor kidney transplantation. N Engl J Med 2010; 363: 1091-1092.
46. Bingaman AW, Murphey CL, Palma-Vargas J, Wright F,. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008; 86: 1864-1868.